These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 33124944)

  • 21. Emergence of Specific
    Singh PK; Singh U; Jain A
    Microb Drug Resist; 2021 May; 27(5):647-651. PubMed ID: 32991238
    [No Abstract]   [Full Text] [Related]  

  • 22. Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran.
    Sayadi M; Zare H; Jamedar SA; Hashemy SI; Meshkat Z; Soleimanpour S; Hoffner S; Ghazvini K
    BMC Infect Dis; 2020 Jun; 20(1):390. PubMed ID: 32487030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco.
    Chaoui I; Oudghiri A; El Mzibri M
    J Glob Antimicrob Resist; 2018 Mar; 12():171-174. PubMed ID: 29033301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis.
    Chien JY; Chien ST; Chiu WY; Yu CJ; Hsueh PR
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4708-16. PubMed ID: 27216062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India.
    Singhal R; Reynolds PR; Marola JL; Epperson LE; Arora J; Sarin R; Myneedu VP; Strong M; Salfinger M
    J Clin Microbiol; 2016 Sep; 54(9):2298-305. PubMed ID: 27335153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Induction in vitro and stability of Mycobacterium tuberculosis resistance to ofloxacin].
    Yang H; Hu Z; Sha W; Lu J; Cui Z; Wang J; Huang X; Xiao H
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Apr; 48(4):318-23. PubMed ID: 24969458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparisons of whole-genome sequencing and phenotypic drug susceptibility testing for Mycobacterium tuberculosis causing MDR-TB and XDR-TB in Thailand.
    Faksri K; Kaewprasert O; Ong RT; Suriyaphol P; Prammananan T; Teo YY; Srilohasin P; Chaiprasert A
    Int J Antimicrob Agents; 2019 Aug; 54(2):109-116. PubMed ID: 30981926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro effects of ciprofloxacin, levofloxacin and moxifloxacin on Mycobacterium tuberculosis isolates.
    Yılmaz FF; Eraç B; Ermertcan Ş; Çavuşoğlu C; Biçmen C; Aktoğu Özkan S; Hoşgör Limoncu M
    Tuberk Toraks; 2018 Mar; 66(1):32-36. PubMed ID: 30020039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.
    Oudghiri A; Karimi H; Chetioui F; Zakham F; Bourkadi JE; Elmessaoudi MD; Laglaoui A; Chaoui I; El Mzibri M
    BMC Infect Dis; 2018 Feb; 18(1):98. PubMed ID: 29486710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.
    Willby M; Sikes RD; Malik S; Metchock B; Posey JE
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5427-34. PubMed ID: 26100699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ofloxacin resistance in Mycobacterium tuberculosis is associated with efflux pump activity independent of resistance pattern and genotype.
    Sun Z; Xu Y; Sun Y; Liu Y; Zhang X; Huang H; Li C
    Microb Drug Resist; 2014 Dec; 20(6):525-32. PubMed ID: 24940805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure.
    Wang JY; Lee LN; Lai HC; Wang SK; Jan IS; Yu CJ; Hsueh PR; Yang PC
    J Antimicrob Chemother; 2007 May; 59(5):860-5. PubMed ID: 17412727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.
    Niward K; Ängeby K; Chryssanthou E; Paues J; Bruchfeld J; Jureen P; Giske CG; Kahlmeter G; Schön T
    J Antimicrob Chemother; 2016 Feb; 71(2):333-8. PubMed ID: 26538509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluoroquinolone resistance among Mycobacterium tuberculosis strains from Karachi, Pakistan: data from community-based field clinics.
    Rafiq Y; Jabeen K; Hasan R; Jafri S; Laiq R; Malik F; Mangi R; Channa A; Hasan Z
    Antimicrob Agents Chemother; 2011 Feb; 55(2):929-30. PubMed ID: 21135180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population-Based Drug Resistance Surveillance of Multidrug-Resistant Tuberculosis in Taiwan, 2007-2014.
    Chuang PH; Wu MH; Fan SY; Lin KY; Jou R
    PLoS One; 2016; 11(11):e0165222. PubMed ID: 27846235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.
    Kambli P; Ajbani K; Sadani M; Nikam C; Shetty A; Udwadia Z; Rodwell TC; Catanzaro A; Rodrigues C
    Tuberculosis (Edinb); 2015 Mar; 95(2):137-41. PubMed ID: 25522842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extensively drug-resistant tuberculosis in Myanmar: burden and mutations causing second-line drug resistance.
    Ei PW; Aung WW; Nyunt WW; Swe TL; Htwe MM; Win SM; Aung ST; Chang CL; Lee HY; Lee JS
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):47-53. PubMed ID: 29297425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
    Nosova EY; Bukatina AA; Isaeva YD; Makarova MV; Galkina KY; Moroz AM
    J Med Microbiol; 2013 Jan; 62(Pt 1):108-113. PubMed ID: 23019190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.
    Veziris N; Truffot-Pernot C; Aubry A; Jarlier V; Lounis N
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3117-22. PubMed ID: 14506018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Burden of Drug resistant Tuberculosis in newly diagnosed Tuberculosis patients of Khyber Pakhtunkhwa, Pakistan.
    Jabbar A; Khan TA; Rehman H; Khan AS; Ahmad S; Khan SN
    J Pak Med Assoc; 2021 Mar; 71(3):912-915. PubMed ID: 34057947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.